Drug Discovery World

JANUARY 30, 2023

There is a significant need for a treatment specifically developed to help manage the progression of this disease. We in the FOP community have been waiting a long time for innovations to treat this disabling disease.” “We in the FOP community have been waiting a long time for innovations to treat this disabling disease.”

Treatment 130

Treatment Disease Clinical Trials Trials 130

Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD).

Treatment 147

Treatment Medical Schools Trials Clinical Trials 147

Drug Discovery World

JULY 24, 2024

The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team. The delivery of fast functional benefit alongside long-term disease stabilisation would make ILB a unique treatment option for this devastating disease.

Trials 130

Trials Disease Hospitals Drugs 130

Drug Discovery World

JUNE 11, 2024

Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative colitis.

Disease 147

Disease Research DNA Laboratories 147

Drug Discovery World

JANUARY 18, 2024

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). million cases of cancer by 2030 1,2.

Treatment 162

Treatment Immune Response Clinical Trials Therapies 162

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

MARCH 6, 2024

This second ODD allows research and development of a therapy for another form of the disease, Isolated Hypomyelination. Dan Williams, CEO at SynaptixBio, said; “This ODD is a huge boost to our efforts in tackling these devastating, life-limiting rare diseases.

FDA 130

FDA Disease Therapies Drugs 130

Drug Discovery World

JANUARY 31, 2024

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

AUGUST 11, 2023

Liverpool School of Tropical Medicine (LSTM) and LifeArc are partnering to launch a new Translational Development Fund to help tackle infectious diseases. million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and neglected tropical diseases.

Disease 130

Disease Therapies Research Hospitals 130

Drug Discovery World

JULY 5, 2024

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS).

Drug Research 204

Drug Research Research Hospitals Drugs 204

Drug Discovery World

OCTOBER 10, 2023

Rejuvenate Biomed, a clinical-stage company advancing therapeutics to delay the onset of age-related diseases, has completed a six-week clinical proof-of-mechanism study with lead candidate RJx-01 for the treatment of sarcopenia.

Disease 130

Disease Pharmacokinetics Treatment Hospitals 130

Drug Discovery World

JUNE 19, 2024

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The treatment was well tolerated and led to a significant improvement in walking distance and 40% reduction in GABAergic medications. “It

Therapies 246

Therapies Disease Hospitals Treatment 246

Drug Discovery World

DECEMBER 11, 2023

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology.

FDA Approval 130

FDA Approval Therapies FDA Disease 130

Drug Discovery World

FEBRUARY 9, 2023

The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children. This is a key part of our overall strategy,” he said. “To

Treatment 130

Treatment Disease Clinical Trials FDA 130

Drug Discovery World

SEPTEMBER 16, 2022

The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases. The post UK company identifies potential new treatment for lupus appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Laboratories Hospitals Disease 130

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

SEPTEMBER 13, 2024

This week, DDW has opened registrations for its webinar ‘ The latest advancements driving neuroscience drug discovery research ’, so our news highlights focus on developments in neuroscience, including a novel drug that has been shown to reduce neuronal death, and a potential disease-modifying treatment for dementia.

Drugs 147

Drugs Disease Hospitals Treatment 147

Drug Discovery World

AUGUST 29, 2024

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. Lecanemab is for slowing progression in mild cognitive impairment or mild dementia due to Alzheimer’s disease (AD) in adults.

Regulations 147

Regulations Hospitals Licensing Licensing 147

KIF1A

MAY 29, 2024

Fortunately, Sloane does not currently have epilepsy, and Megan hopes this treatment will prevent it’s onset as her disease progresses. On the day of the treatment, they checked into the hospital where Sloane was administered sedation medication. The post Sloane’s 1st ASO treatment appeared first on KIF1A.

Treatment 52

Treatment Doctors Hospitals Therapies 52

Drug Discovery World

SEPTEMBER 15, 2022

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. CRC is the second most common cause of cancer mortality, accounting for 881,000 deaths globally in 2018, and patients with metastatic disease have a five-year survival rate of just 11%.

Trials 130

Trials Treatment Clinical Trials Hospitals 130

Drug Target Review

DECEMBER 29, 2023

Scientists in China have published their findings 1 regarding novel biomarkers, which they hope will benefit patients by identifying the disease at an earlier stage. Diabetic kidney disease DKD is a major microvascular complication of type 2 diabetes mellitus (T2DM). References Du S, Zhai L, Ye S, et al. Science China Life Sciences.

Disease 126

Disease Science Hospitals Treatment 126

Drugs.com

MARCH 21, 2024

THURSDAY, March 21, 2024 -- People with heart disease can stay healthier if they address their emotional problems as well as their physical ailments, a new study says.Treating anxiety and depression reduced ER visits and hospitalizations among.

Treatment 116

Treatment Hospitals Disease 116

Drug Discovery World

SEPTEMBER 13, 2024

The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University, UK.

Hospitals 147

Hospitals Clinical Research Treatment Research 147

Drug Discovery World

JULY 13, 2022

The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC). . Many people with sickle cell disease experience recurrent painful crises which can result in hospital admission.

Treatment 130

Treatment Hospitals Disease International 130

Drugs.com

MAY 20, 2024

MONDAY, May 20, 2024 -- Women treated for infertility were twice as likely as those who conceived naturally to be hospitalized with heart disease within a year of delivery, recent research shows.They are particularly likely to land in the hospital.

Treatment 69

Treatment Hospitals Disease Research 69

Drug Discovery World

JULY 15, 2024

The treatment was the last resort to slow down systemic lupus erythematosus (SLE), which is a serious autoimmune disease that was attacking the patient’s body and seriously affected her ability to lead a normal life. Her kidney and lupus values improved from the third week after the treatment,” said Dr Krickau. “We

Therapies 130

Therapies Disease Treatment Hospitals 130

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. Espen integrates clinical and research expertise as Director of Medical Affairs.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Broad Institute

JANUARY 25, 2024

They found significant associations between the thinning of different retinal layers and increased risk of developing ocular, cardiac, pulmonary, metabolic, and neuropsychiatric diseases and identified genes that are associated with retinal layer thickness. Their findings are published in Science Translational Medicine. “We

Disease 124

Disease Research Medical Schools Science 124

Drug Discovery World

JUNE 25, 2024

The paper was co-authored by analytics company Phesi and Dr Yi-Bin Chen, Director for the Blood and Marrow Transplant Program at Massachusetts General Hospital. Phesi created a digital twin for chronic graft versus host disease (cGvHD) in the primary treatment setting.

Clinical Trials 147

Clinical Trials Trials Hospitals Clinical Research 147

Drug Discovery World

JUNE 20, 2023

One analysis from AstraZeneca’s ZORA study showed that discontinuation of RAASi treatment following a HK episode in cardiorenal patients with chronic kidney disease (CKD) and/or heart failure (HF) was still common in clinical practice in the US and Japan despite guidelines recommending maintained treatment.

Hospitals 130

Hospitals Treatment Disease Therapies 130

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Discovery World

JULY 17, 2024

As well as Covid-19, it has the potential to treat other respiratory infections such as those caused by influenza or bacterial pneumonia, and even other lung diseases such as pulmonary fibrosis.

Clinical Trials 130

Clinical Trials Drugs Hospitals Trials 130

biobide

FEBRUARY 2, 2024

Pediatric cancers exhibit differences at the genetic level compared to the same form of adult disease, which may influence the selected treatment. Zebrafish Pioneers Advance in Pediatric Cancer Research and Treatment Increasing the survival rate is the primary goal when screening for cancer drugs.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Drug Discovery World

OCTOBER 17, 2023

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. For HCC patients with concurrent inferior vena cava tumour thrombus, treatment options are limited and overall prognosis is poor. months postoperatively.

Therapies 162

Therapies Hospitals Treatment Virus 162

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

Drug Discovery World

SEPTEMBER 17, 2024

Where do you work, and can you tell us what you’re working on at the moment?  I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet medical needs and large addressable markets, with programmes in oncology, infectious diseases and endocrinology.

Research 221

Research Clinical Trials Disease Trials 221

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel Phase II trial incorporating Hu14.18 and three-year event-free (EFS) of 73.7%.

Licensing 246

Licensing Licensing Hospitals Therapies 246